Neumora Therapeutics, Common Stock Debt To Equity

NMRA Stock   1.40  0.02  1.45%   
Neumora Therapeutics, Common fundamentals help investors to digest information that contributes to Neumora Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Neumora Stock. The fundamental analysis module provides a way to measure Neumora Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neumora Therapeutics, stock.
Last ReportedProjected for Next Year
Debt To Equity 0.01  0.01 
The current year's Debt To Equity is expected to grow to 0.01.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Neumora Therapeutics, Common Company Debt To Equity Analysis

Neumora Therapeutics,'s Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Current Neumora Therapeutics, Debt To Equity

    
  0.006778  
Most of Neumora Therapeutics,'s fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neumora Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Neumora Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Neumora Therapeutics, is extremely important. It helps to project a fair market value of Neumora Stock properly, considering its historical fundamentals such as Debt To Equity. Since Neumora Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neumora Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neumora Therapeutics,'s interrelated accounts and indicators.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition

Neumora Total Stockholder Equity

Total Stockholder Equity

301.42 Million

At present, Neumora Therapeutics,'s Total Stockholder Equity is projected to increase significantly based on the last few years of reporting.

Neumora Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neumora Therapeutics,'s direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neumora Therapeutics, could also be used in its relative valuation, which is a method of valuing Neumora Therapeutics, by comparing valuation metrics of similar companies.
Neumora Therapeutics, is currently under evaluation in debt to equity category among its peers.

Neumora Fundamentals

About Neumora Therapeutics, Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Neumora Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neumora Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neumora Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Neumora Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neumora Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neumora Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neumora Therapeutics, Common Stock:
Check out Neumora Therapeutics, Piotroski F Score and Neumora Therapeutics, Altman Z Score analysis.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neumora Therapeutics,. If investors know Neumora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neumora Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.53)
Return On Assets
(0.41)
Return On Equity
(0.64)
The market value of Neumora Therapeutics, is measured differently than its book value, which is the value of Neumora that is recorded on the company's balance sheet. Investors also form their own opinion of Neumora Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Neumora Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neumora Therapeutics,'s market value can be influenced by many factors that don't directly affect Neumora Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neumora Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Neumora Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neumora Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.